The FDA has granted 501 (k) clearance to the EXENT® System, a fully automated device for assessing monoclonal gammopathies, ...

The FDA has accepted the new drug application (NDA) of the synthetic, targeted radiotherapeutic agent 177 Lu-edotreotide (ITM ...

At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Meara explored the ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...

Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...

International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...

The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...

FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...